# Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

> **NCT01396447** · PHASE2 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 584 (actual)

## Conditions studied

- Depression, Bipolar

## Interventions

- **DRUG:** Placebo
- **DRUG:** Cariprazine

## Key facts

- **NCT ID:** NCT01396447
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-26
- **Primary completion:** 2014-01-10
- **Final completion:** 2014-01-10
- **Target enrollment:** 584 (ACTUAL)
- **Last updated:** 2018-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396447, "Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01396447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*